354 related articles for article (PubMed ID: 24484652)
1. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir.
Anwar M; Weinberg V; Chang AJ; Hsu IC; Roach M; Gottschalk A
Radiat Oncol; 2014 Feb; 9():42. PubMed ID: 24484652
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy versus conventionally fractionated external beam radiotherapy for low- and intermediate-risk prostate cancer.
Lee SH; Kim HJ; Kim WC
Asia Pac J Clin Oncol; 2016 Dec; 12(4):388-395. PubMed ID: 27461444
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer.
Phak JH; Kim HJ; Kim WC
Prostate Int; 2016 Mar; 4(1):25-9. PubMed ID: 27014661
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.
Jabbari S; Weinberg VK; Kaprealian T; Hsu IC; Ma L; Chuang C; Descovich M; Shiao S; Shinohara K; Roach M; Gottschalk AR
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):228-34. PubMed ID: 21183287
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiotherapy as boost for organ-confined prostate cancer.
Katz AJ; Santoro M; Ashley R; Diblasio F; Witten M
Technol Cancer Res Treat; 2010 Dec; 9(6):575-82. PubMed ID: 21070079
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost and whole pelvic radiotherapy for intermediate- and high-risk prostate cancer.
Kim HJ; Phak JH; Kim WC
Asia Pac J Clin Oncol; 2017 Feb; 13(1):21-27. PubMed ID: 26969216
[TBL] [Abstract][Full Text] [Related]
7. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
8. High-Dose Robotic Stereotactic Body Radiotherapy in the Treatment of Patients With Prostate Cancer: Preliminary Results in 26 Patients.
Pontoriero A; Iatì G; Mondello S; Midili F; Siragusa C; Brogna A; Ielo I; Anastasi G; Magno C; Pergolizzi S; De Renzis C
Technol Cancer Res Treat; 2016 Feb; 15(1):179-85. PubMed ID: 25586517
[TBL] [Abstract][Full Text] [Related]
9. Prostate specific antigen kinetics following robotic stereotactic body radiotherapy for localized prostate cancer.
Kole TP; Chen LN; Obayomi-Davies O; Kim JS; Lei S; Suy S; Dritschilo A; Collins SP
Acta Oncol; 2015 Jun; 54(6):832-8. PubMed ID: 25467965
[TBL] [Abstract][Full Text] [Related]
10. Long-term results and PSA kinetics after robotic SBRT for prostate cancer: multicenter retrospective study in Korea (Korean radiation oncology group study 15-01).
Park Y; Park HJ; Jang WI; Jeong BK; Kim HJ; Chang AR
Radiat Oncol; 2018 Nov; 13(1):230. PubMed ID: 30470253
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.
Chen LN; Suy S; Uhm S; Oermann EK; Ju AW; Chen V; Hanscom HN; Laing S; Kim JS; Lei S; Batipps GP; Kowalczyk K; Bandi G; Pahira J; McGeagh KG; Collins BT; Krishnan P; Dawson NA; Taylor KL; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2013 Mar; 8():58. PubMed ID: 23497695
[TBL] [Abstract][Full Text] [Related]
12. Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost.
Jabbari S; Weinberg VK; Shinohara K; Speight JL; Gottschalk AR; Hsu IC; Pickett B; McLaughlin PW; Sandler HM; Roach M
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):36-42. PubMed ID: 19409729
[TBL] [Abstract][Full Text] [Related]
13. Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy.
Kestin LL; Vicini FA; Ziaja EL; Stromberg JS; Frazier RC; Martinez AA
Cancer; 1999 Oct; 86(8):1557-66. PubMed ID: 10526285
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen kinetics after stereotactic body radiotherapy as monotherapy or boost after whole pelvic radiotherapy for localized prostate cancer.
Kim HJ; Phak JH; Kim WC
Prostate Int; 2015 Dec; 3(4):118-22. PubMed ID: 26779457
[TBL] [Abstract][Full Text] [Related]
15. Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients.
Romesser PB; Pei X; Shi W; Zhang Z; Kollmeier M; McBride SM; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):59-67. PubMed ID: 29254782
[TBL] [Abstract][Full Text] [Related]
16. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
17. A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806).
Isfahanian N; Lukka H; Dayes I; Quan K; Schnarr KL; Douvi G; Goldberg M; Wright J; Swaminath A; Chow T; Diamond K; Cutz JC; Kavsak P; Thabane L; Tsakiridis T
Clin Genitourin Cancer; 2020 Aug; 18(4):e410-e415. PubMed ID: 32265129
[TBL] [Abstract][Full Text] [Related]
18. Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes.
Zelefsky MJ; Gomez DR; Polkinghorn WR; Pei X; Kollmeier M
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):529-33. PubMed ID: 23523323
[TBL] [Abstract][Full Text] [Related]
19. Disease control outcomes of stereotactic body radiation therapy or moderate hypo-fractionation for prostate cancer: Real-world experience at two Canadian centers.
Hu HP; Anagnostopoulos G; Gouran-Savadkoohi M; Dayes I; Ishkanian A; Hallock A; Lukka H; Quan K; Schnarr K; Cuthbert D; Goldberg M; Chang YM; Tsakiridis T
Prostate; 2024 Feb; 84(2):193-202. PubMed ID: 37880911
[TBL] [Abstract][Full Text] [Related]
20. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA
Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
